Pharmaceuticals
NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
TEL AVIV, Israel, March 26, 2025 /PRNewswire/ -- Neurim Pharmaceuticals
2025-03-26 17:00
3188
GenScript Biotech Earns EcoVadis Bronze Medal for the Second Consecutive Year, Ranking Above 83% of Companies
PISCATAWAY, N.J., March 26, 2025 /PRNewswire/ -- GenScript Biotech Corporation (GenScript), a global leader in life sciences research, manufacturing technologies and production services, has been awarded the EcoVadis Bronze Medal for the second year in a row, recognizing its strong sustainability...
2025-03-26 14:49
1781
NUS researchers develop microneedle technology to accelerate diabetic wound healing
'Sponge-like' microneedle patches deliver bioactive ingredients and reduce inflammation in slow- and non-healing wounds SINGAPORE, March 26, 2025 /PRNewswire/ -- Diabetic wounds often lead to severe complications that can result in amputations. These chronic and non-healing wounds are marked by ...
2025-03-26 14:21
2521
Fosun Pharma Announces 2024 Annual Results
Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global pharmaceutica...
2025-03-26 10:29
2926
CStone to Showcase Five Latest Research Achievements at AACR 2025
SUZHOU, China, March 25, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place inChicago. CStone will showcase its latest preclinical studies on five internally developed innovative candidates, including the trispecific ...
2025-03-26 08:15
2111
AccurEdit Therapeutics' LNP-based In Vivo Gene Editing Product ART001 Obtained Orphan Drug Designation from the FDA
CAMBRIDGE, Mass., March 25, 2025 /PRNewswire/ -- AccurEdit Therapeutics today announced that its innovativein vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). ART001, which utilizes lipid nanoparticle (LNP) technolog...
2025-03-25 19:00
1842
WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024
* Revenue increased by 90.8% YoY to RMB 4,052 million * Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023 * Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of 26.4%, a 13.0 percentag...
2025-03-24 22:45
3337
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically...
2025-03-24 22:30
1850
Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval
NEW YORK, March 24, 2025 /PRNewswire/ -- On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068)—received Fast Track Des...
2025-03-24 21:00
1621
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025
NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing Phase I clinical trial of ...
2025-03-24 20:30
2223
SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS
BEIJING, March 24, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) appl...
2025-03-24 20:00
3309
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. T...
2025-03-24 08:15
2325
Clover Announces U.S. IND Clearance and Initiation of Revaccination Clinical Study for RSV Vaccine Candidate SCB-1019
-- U.S. IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform -- -- Evaluation of SCB-1019 as part of a respiratory combination Trimer-Tagged PreF vaccine (RSV + hMPV ± PIV3...
2025-03-24 07:56
2174
Syneron Bio Announces Strategic Collaboration with AstraZeneca
BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug biotech company, announced today a strategic collaboration with the global biopharmaceutical leader AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of chronic ...
2025-03-21 20:02
2469
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive Year
* Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) * Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 20, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2...
2025-03-21 08:30
1981
Seegene Unveils HPV Genotyping Solution at EUROGIN 2025
- Presented a roadmap to enhance screening reliability at the world's leading multidisciplinary HPV congress held inPortugal from March 16-19 - Demonstrated how self-collected samples for HPV testing can bridge gaps in cervical cancer screening and advance HPV screening goals SEOUL, South K...
2025-03-20 21:00
2109
LISCure Biosciences Secures World's First Regulatory Approval for Hair Health Probiotic as an functional Ingredient
SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- LISCure Biosciences Inc. ("LISCure") announced on the2025 Feb that it has received approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Mobiome®, a proprietary probiotic ingredient developed to promote hair health. Securing th...
2025-03-20 21:00
2229
TiumBio's Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development
* Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (controlled ovarian stimulation) inChina SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- TiumBio (KOSDAQ: 321550), a clinical-stage biopharmace...
2025-03-20 20:00
1919
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
* Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL * The combination of golidocitinib and PD-1 antibody showed synergistic anti-tumor effects in anti-PD-1-resistant NSCLC SHANGHAI, March 20, 2025 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmac...
2025-03-20 18:00
1859
111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results
* Achieved First-Ever Annual Operating Profit * Bottom Line Improved by RMB332.7 Million YoY in 2024 * Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 * Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoY * Achieved Fi...
2025-03-20 13:00
3872
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 316 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 300 media titles]
2026-01-27 13:00
AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 299 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
